News

News // Emery Pharma and AbVacc Announce Strategic Collaboration to Develop Super Fast-Acting Intranasal Naloxone

Emery Pharma and AbVacc Announce Strategic Collaboration to Develop Super Fast-Acting Intranasal Naloxone

San Francisco, CA, and Rockville, MD –Emery Pharma, a leading pharmaceutical research organization in the San Francisco Bay Area, and AbVacc, a renowned biotechnology company headquartered in Rockville, Maryland, are pleased to announce a strategic collaboration to develop a super fast-acting intranasal naloxone. This innovative product is designed to address a critical public health need by rapidly and effectively reversing opioid overdoses.

The collaboration capitalizes on Emery Pharma’s expertise in pharmaceutical research, drug development, and regulatory compliance, alongside AbVacc’s proficiency in creating preclinical pharmacokinetic and efficacy models. The partnership’s primary objectives include optimizing the intranasal naloxone formulation, evaluating its pharmacokinetics and efficacy in preclinical studies, and advancing the product to human clinical trials for eventual FDA approval and commercialization.

Dr. Ron Najafi, CEO of Emery Pharma, commented:

At Emery Pharma, we are deeply committed to addressing the opioid epidemic through innovative solutions. Our partnership with AbVacc combines our advanced pharmaceutical development capabilities with their exceptional expertise in pharmacokinetics to create a life-saving, super fast-acting intranasal naloxone. We are excited to collaborate with Dr. Aman and the outstanding team at AbVacc to accelerate this project and bring hope to those affected by opioid addiction.”

Dr. Javad Aman, CEO of AbVacc, added:

This collaboration with Emery Pharma presents a remarkable opportunity to address one of the most urgent public health challenges of our time. Patients are waiting, and our teams are working at the speed of light to develop a solution that could save countless lives. Together, we are leveraging our expertise to make this vision a reality and provide a transformative product to combat the opioid crisis.”

This partnership reflects both companies’ commitment to leveraging innovation and scientific excellence to address the ongoing opioid epidemic. Emery Pharma and AbVacc share a unified vision of delivering transformative healthcare solutions that save lives and improve patient outcomes globally.

About Emery Pharma
Emery Pharma is a contract research organization based in Alameda, California, specializing in drug discovery, bioanalysis, and regulatory compliance. With state-of-the-art facilities and a dedicated team of scientists, Emery Pharma partners with pharmaceutical, biotechnology, and medical device companies to develop and advance innovative healthcare solutions. For more information, visit emerypharma.com or contact Dr. Hamid Mobedi, Senior Research Scientist at (510) 899-8814 or email: info@emerypharma.com

About AbVacc
AbVacc is a biotechnology company headquartered in Rockville, Maryland, focusing on developing preclinical models to evaluate therapeutic efficacy and pharmacokinetics. With a mission to address unmet medical needs and improve patient outcomes, AbVacc leverages cutting-edge science and technology to advance the development of life-saving treatments. For more information, visit abvacc.com.

Emery Pharma

Emery Pharma is a full-service contract research laboratory, specializing in analytical, bioanalytical chemistry, microbiology & cell biology services, custom synthesis, and general R&D and cGMP/GLP support.